Stefano Mancon

MD, Urology Resident @HUNIMED, Milan, Italy | Former Research Fellow @MedUni_Wien, Vienna, Austria | Fellow @FPuigvert, Barcelona, Spain

[Mirrors of Medicine @mirrorsmed]

Oncological outcomes of deferred systemic therapy for patients with metastatic renal cell carcinoma: A systematic review and quantitative analysis

https://t.co/QqTvmq8uta

This systematic review suggests that active surveillance or other deferred systemic therapy strategies are viable and safe options for carefully selected patients with metastatic renal cell carcinoma, particularly those with favorable prognostic features. Across 1⃣5⃣ studies including nearly 3,000 patients, approximately half of patients avoided systemic therapy for up to three years without compromising overall survival, which was comparable to outcomes with immediate treatment. Favorable Rini risk scores were associated with better outcomes, supporting patient selection as a key factor.

Although the evidence is limited by study heterogeneity, selection bias, and reliance on tyrosine kinase inhibitor–era data, these findings highlight the potential of personalized, observation-based approaches to reduce overtreatment while maintaining oncologic efficacy in mRCC. #KidneyCancer

Ichiro Tsuboi
@dr_rajwa
@miszczyk_marcin
@fazekasMD
@Mehdi_Kardoust
@ManconS_
@E_Laukhtina
@K_Tatsushi
@kensuke_bekku
@PiotrChlosta
@DrShariat
@Ric_Campi

[Fundació Puigvert Barcelona @FPuigvert]

Today in #PiS: "A Global Perspective on the Adoption of different Robotic Platforms in #UroOnco Surgery". This work was to study the usage of robotic systems around the globe, including Fundació #Puigvert: 🥇The da Vinci is the most used worldwide.
🔗https://t.co/rXWwKkBA5u
@joanfundi

[Óscar Rodríguez Faba @RodriguezFaba]

In @actasurologicas we publish a systematic review on the impact of opium consumption in bladder cáncer
https://t.co/PEBIoVQguL

[Stefano Mancon @ManconS_]

Impact of opium on bladder cancer incidence: A systematic review and m... https://t.co/MkXuc8Ags4

[Óscar Rodríguez Faba @RodriguezFaba]

In the special issue on urothelial cancer @actasurologicas an interesting OPEN ACCESS review by @EAU_YAUrotheli .Circulating tumor DNA in muscle-invasive bladder cancer: A systematic ... https://t.co/wmSj5eQ5K8

[Joan Palou Redorta @joanfundi]

Training continues, new incorporacions in @Fundacio Puigvert in December: @ManconS_ from Italy, ⁦@VicenteRojasUro⁩ from Chile and ⁦@eminmpolat⁩ from Turquia.
Enjoy our center and #Barcelona!

[Eur Urol Focus @EurUrolFocus]

Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.

Does this change your practice?

[European Urology @EUplatinum]

Words of Wisdom Wednesday: Re: Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial by @ManconS_ et al

Check out the summary below and read the full article here: https://t.co/EjqmSrQsvB

#MedTwitter #UroSoMe #EU #WoWWednesday

[Leonard Perpepaj @leonardperpepaj]

Attending the EAU Endoscopic Stone Treatment Programme: Step 2 was a wonderful experience. I'm grateful for the endourology training in Hamburg and the chance to make new friends.
#esuests2 @Uroweb @UrowebESU @kallidonis_p @LaurianDragos @NicolaMacchione @ManconS_